For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Reduced-volume radiotherapy for patients with localized intracranial nongerminoma germ cell tumors.

TitleReduced-volume radiotherapy for patients with localized intracranial nongerminoma germ cell tumors.
Publication TypeJournal Article
Year of Publication2017
AuthorsDe B, Cahlon O, Dunkel IJ, De Braganca KC, Khakoo Y, Gilheeney SW, Souweidane MM, Wolden SL
JournalJ Neurooncol
Volume134
Issue2
Pagination349-356
Date Published2017 Sep
ISSN1573-7373
KeywordsAdolescent, Adult, Brain Neoplasms, Child, Child, Preschool, Combined Modality Therapy, Cranial Irradiation, Female, Follow-Up Studies, Humans, Male, Neoplasm Recurrence, Local, Neoplasms, Germ Cell and Embryonal, Pinealoma, Retrospective Studies, Survival Analysis, Young Adult
Abstract

Craniospinal irradiation is standard radiotherapy (RT) for localized intracranial nongerminoma germ cell tumors (NGGCT). Given its toxicity, there is interest in using smaller fields. We examined outcomes of NGGCT patients receiving reduced-volume RT at a single institution. Records of 16 patients who received reduced-volume RT as part of definitive treatment between 1996 and 2016 were reviewed. Median age at presentation was 10.8 years (range 4.6-41.0 years). Ten patients had pineal tumors and 6 had suprasellar tumors. All received chemotherapy and 9 patients received second-look surgery thereafter. RT volume was tumor-only to a median of 54 Gy (range 50.4-54 Gy) in 3 patients and whole-ventricle irradiation to a median of 30.6 Gy (range 30.6-36 Gy) with a boost to 54 Gy in 13 patients. Median follow-up was 4.1 years (range 1.9-19.3 years). Three patients recurred locally at a median 9.9 months (range 9.6-10.6 months) after diagnosis, and one of these developed leptomeningeal relapse after 30 months. One patient expired from disease 2.6 years post-diagnosis and another due to stroke 19.3 years post-diagnosis. Fourteen patients are alive with no evidence of disease. Kaplan-Meier estimates of the 4-year overall survival and failure-free survival are 92% (95% confidence interval [CI], 57-99%) and 81% (95% CI 53-94%), respectively. Excellent disease control was observed in these patients with no initial relapses outside of these RT fields. The results of ACNS1123 may better delineate patterns of failure and identify subgroups likely to benefit from this approach.

DOI10.1007/s11060-017-2532-7
Alternate JournalJ Neurooncol
PubMed ID28660318
PubMed Central IDPMC5711536
Grant ListP30 CA008748 / CA / NCI NIH HHS / United States
P30 CA008748 / / National Institutes of Health/National Cancer Institute Cancer Center Support Grant /